VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent for Use of Stem Cells to Treat Cancer and Autoimmune D...
June 11 2018 - 8:30AM
Patent Covers Methods for Producing Blood Cells,
Platelets and Bone Marrow Stem Cells
VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a clinical-stage
biopharmaceutical company developing new generation medicines for
depression and other central nervous system (CNS) diseases and
disorders, and its wholly-owned stem cell technology-focused
subsidiary, VistaStem Therapeutics, Inc., today announced that
the Japanese Patent Office (JPO) has issued a Notice of Allowance
for a patent related to certain methods for producing blood cells,
platelets and bone marrow stem cells. This new patent will be the
Japanese counterpart to U.S. Patent No. 9,834,754, issued by the
U.S. Patent and Trademark Office (USPTO) in December 2017.
The new Japanese patent covers methods for producing
hematopoietic precursor stem cells from human pluripotent stem
cells. Hematopoietic precursor stem cells give rise to all of the
blood cells and most of the bone marrow cells in the body. The
technology could provide cells with the potential to support
therapies for multiple diseases and disorders, such as, among
others, cancer, including CAR T-cell cancer immunotherapy, and
autoimmune disorders. In addition, the new patent covers
foundational technology that may provide approaches for producing
bone marrow stem cells suitable for bone marrow
transplantation.
Dr. Gordon Keller, Director of the McEwen Centre for
Regenerative Medicine, one of the world's leading centers for stem
cell and regenerative medicine research and part of the University
Health Network (UHN) in Toronto, discovered the stem cell
technology covered by this patent. VistaGen holds an exclusive
license to this patent from UHN.
About VistaGenVistaGen Therapeutics, Inc. is a
clinical-stage biopharmaceutical company developing new generation
medicines for depression and other CNS diseases and disorders with
high unmet need. VistaGen's lead CNS product candidate, AV-101, is
an oral N-methyl-D-aspartate receptor glycine B (NMDAR GlyB)
antagonist in Phase 2 clinical development in the United States,
for Major Depressive Disorder and other CNS indications.
About VistaStemVistaStem Therapeutics is
VistaGen's wholly-owned subsidiary focused on applying stem cell
technology to develop and commercialize proprietary new chemical
entities (NCEs) for VistaGen’s CNS pipeline and out-licensing, as
well as cellular and regenerative therapies for a range of diseases
and disorders involving blood and bone marrow cells, chondrocytes
and cartilage, and heart and liver cells, including autoimmune
disorders, cancer, heart and liver disease, osteoarthritis and
joint injury.
For more information, please visit www.vistagen.com and connect
with VistaGen on Twitter, LinkedIn and Facebook.
Forward-Looking StatementsThis release contains
various statements concerning VistaGen's future expectations, plans
and prospects, including without limitation, our expectations
regarding potential future strategic collaborations involving our
stem cell technology and our intellectual property and commercial
protection of our product candidates. These statements constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995. These forward-looking statements are neither promises nor
guarantees of future performance and are subject to a variety of
risks and uncertainties, many of which are beyond our control and
may cause actual results to differ materially from those
contemplated in these forward-looking statements. Among these risks
is the possibility that (i) we may encounter unexpected adverse
events that cause us to discontinue further development of our stem
cell technology for therapeutic applications, (ii) we may not have
access to or be able to secure substantial additional capital to
support our operations, including further research and development
of VistaStem’s stem cell technology for cellular therapy or
regenerative medicine applications described in this release; and
(iii) we, or a potential future collaborator, may encounter
technical and other unexpected hurdles in the production of cells
for research and development and/or cellular therapy or
regenerative medicine applications. Certain other risks are more
fully discussed in the section entitled "Risk Factors" in our most
recent annual report on Form 10-K, and subsequent quarterly reports
on Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in our other filings
with the Securities and Exchange Commission (SEC). Our SEC filings
are available on the SEC's website at www.sec.gov. In addition, any
forward-looking statements represent our views only as of the
issuance of this release and should not be relied upon as
representing our views as of any subsequent date. We explicitly
disclaim any obligation to update any forward-looking
statements.
Company ContactMark A. McPartlandVistaGen
Therapeutics Inc.Phone: +1 (650) 577-3600Email: IR@vistagen.com
Investor ContactValter Pinto / Allison SossKCSA
Strategic CommunicationsPhone: +1 (212) 896-1254/+1 (212)
896-1267Email: VistaGen@KCSA.com
Media ContactCaitlin Kasunich / Lisa LipsonKCSA
Strategic CommunicationsPhone: +1 (212) 896-1241/+1 (508)
843-6428Email: VistaGen@KCSA.com
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024